Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alxn2050 + fluconazole
- Development stage
- Phase 1
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ALXN2050 + fluconazole** is a combination of ALXN2050, an investigational small molecule inhibitor developed for generalized myasthenia gravis (gMG), and fluconazole, a widely-used triazole antifungal agent marketed as Diflucan. ALXN2050 selectively inhibits the alternative pathway of complement C5 activation, reducing destructive immune activity implicated in autoimmune conditions. Fluconazole exerts its antifungal activity by inhibiting fungal cytochrome P450 (CYP51), impairing ergosterol synthesis and fungal cell membrane formation. In drug-drug interaction trials, fluconazole may affect ALXN2050 pharmacokinetics due to its action as a CYP2C9, CYP3A4, and CYP2C19 inhibitor, potentially increasing exposure to ALXN2050.
- Other names
- ALXN2050ALXN-2050ALXN 2050fluconazoleALXN2050 + fluconazole
02
Targets
CYP51A1 (Sterol 14α-demethylase)C5
Beyond the preview
Go deeper on alxn2050 + fluconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alxn2050 + fluconazole.